Luis Paz‐Ares

Research interests

Publications

• Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

  Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.22.01990

• Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

  The Lancet · 2023 · https://doi.org/10.1016/s0140-6736(23)00221-0

• Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2307980

• Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00518-6

• Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2112431

• First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

  The Lancet Oncology · 2021 · 10.1016/s1470-2045(20)30641-0

• Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30539-8

• IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

  Journal of Thoracic Oncology · 2020 · 10.1016/j.jtho.2020.01.005

• Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30539-8

• A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

  Journal of Thoracic Oncology · 2020 · 10.1016/j.jtho.2020.06.015

• Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1910231

• Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30691-6

• Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

  The Lancet · 2019 · 10.1016/s0140-6736(19)32222-6

• First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.01042

• Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

  Annals of Oncology · 2018 · 10.1093/annonc/mdx703

• Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1809697

• Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1801946

• Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1810865

• Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1709937

• First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

  The Lancet · 2017 · 10.1016/s0140-6736(17)30123-x

• First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1613493

• Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2017.74.3062

• Current Challenges in Cancer Treatment

  Clinical Therapeutics · 2016 · 10.1016/j.clinthera.2016.03.026

• Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(16)30033-x

• Lung cancer: current therapies and new targeted treatments

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)30958-8

• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1504627

• PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.47.1102

• First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

  Cancer Discovery · 2013 · 10.1158/2159-8290.cd-12-0429

• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(11)70393-x

• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  New England Journal of Medicine · 2009 · 10.1056/nejmoa0904554

Current projects

No projects listed.